Name | Title | Contact Details |
---|---|---|
Douglas Bain |
Chief Technology Officer | Profile |
A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics` Trilliumâ„¢ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.
At Onyx Pharmaceuticals, an Amgen subsidiary, our imperative is to build a leading cancer therapeutics company like no other, working toward a unified goal that drives us forward…to deliver breakthrough cancer treatments to patients with the urgency they deserve. By working in collaboration with patient advocacy groups, healthcare providers and business partners, we push the boundaries of science and cancer therapeuticdevelopment.
Veranova is a global leader in process development and manufacturing of active pharmaceutical ingredients (APIs), focused on specialty niches with expertise in highly regulated and complex chemistries. Veranova is headquartered in Wayne, PA and has operations in North America and Europe.